David M. Jablons
University of California, San Francisco
330 Papers
3.2K Citations
David M. Jablons is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 65, co-authored 317 publications. Previous affiliations of David M. Jablons include University of California, Los Angeles & University of California.
Chat about Author
Papers
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson,Louis Fehrenbacher,William Novotny,Roy S. Herbst,John Nemunaitis,David M. Jablons,Corey J. Langer,Russell F. DeVore,Jacques Gaudreault,Lisa A. Damico,Eric Holmgren,Fairooz F. Kabbinavar +11 more
TL;DR: Bvacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer.
2K
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Ashley Maynard,Caroline E. McCoach,Julia K Rotow,Lincoln Harris,Franziska Haderk,D. Lucas Kerr,Elizabeth A. Yu,Erin L. Schenk,Weilun Tan,Alexander Zee,Michelle Tan,Philippe Gui,Tasha Lea,Wei Wu,Anatoly Urisman,Kirk D. Jones,Rene Sit,Pallav K. Kolli,Eric J. Seeley,Yaron Gesthalter,Daniel D. Le,Kevin A. Yamauchi,David M. Naeger,David M. Naeger,Sourav Bandyopadhyay,Khyati N. Shah,Lauren Cech,Nicholas J. Thomas,Anshal Gupta,Mayra Gonzalez,Hien Do,Lisa Tan,Bianca Bacaltos,Rafael Gomez-Sjoberg,Matthew A. Gubens,Thierry Jahan,Johannes R. Kratz,David M. Jablons,Norma Neff,Robert C. Doebele,Jonathan S. Weissman,Collin M. Blakely,Spyros Darmanis,Trever G. Bivona +43 more
TL;DR: How therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes is highlighted, with scRNA-seq illuminating targetable oncogenes beyond those detected clinically.
528
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
Biao He,Liang You,Kazutsugu Uematsu,Keling Zang,Zhidong Xu,Amie Y. Lee,Joseph F. Costello,Frank McCormick,David M. Jablons +8 more
TL;DR: In this article, the authors identify frequent hypermethylation in CpG islands of the functional SOCS-3 promoter that correlates with its transcription silencing in cell lines (lung cancer, breast cancer, and mesothelioma) and primary lung cancer tissue samples.
414
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou,Michael Peyton,Biao He,Changnian Liu,Luc Girard,Eian Caudler,Yvonne Lo,Frédéric Baribaud,Iwao Mikami,Noemi Reguart,Gengjie Yang,Yanlong Li,Wenqing Yao,Kris Vaddi,Adi F. Gazdar,Steven Friedman,David M. Jablons,Robert C. Newton,Jordan S. Fridman,John D. Minna,Peggy Scherle +20 more
TL;DR: The results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.
404
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone,Prasad S. Adusumilli,H. Richard Alexander,Paul Baas,Fabrizio Bardelli,Angela Bononi,Raphael Bueno,Emanuela Felley-Bosco,Françoise Galateau-Sallé,David M. Jablons,Aaron S. Mansfield,Michael Minaai,Marc de Perrot,Patricia A. Pesavento,Valerie W. Rusch,David T. Severson,Emanuela Taioli,Anne Tsao,Gavitt A. Woodard,Haining Yang,Marjorie G. Zauderer,Harvey I. Pass +21 more
TL;DR: Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies.
396